VIVES is a multi-sector fund that invests in projects with a positive societal impact
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
Botalys has developed a technology (vertical farming) that allows to produce rare plants and ingredients for the food supplement, cosmetics and pharmacy industries. Vertical farming allows them to...
iTeos Therapeutics targets the tumor microenvironment to boost immune cell efficiency in cancer eradication.
Immunotherapy is a revolutionary approach to cancer treatment that aims to educate the...
Chris Buyse, Co founder and Managing Partner of Fund+ :
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Denis Périquet, CEO Tessares :
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Philippe Mengal, past CEO Greenwatt :
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
La start-up e-peas continue à asseoir sa réputation en tant que fournisseur de référence de solutions avancées de collecte d’énergie, avec la clôture d’un nouveau tour de financement.
Soutenue par
La plate-forme technologique unique de régénération tissulaire 3M3 génère plusieurs produits candidats : autologue, prêt à l'emploi et miARN / exosome.
Mont-Saint Guibert, Belgique, 4 juin 2020 :